Browsing by Subject "Dermatology"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Evaluation of Sensitive Skin in the Asian Population(2008-12-01) Nguyen, Hanh Thuy; Patricia Gwirtz; Dan Dimitrijevich; Hanh PhamNguyen, Hanh T., Evaluation of Sensitive Skin in the Asian Population. Masters of Science (Clinical Research Management), December, 2008, pp. 80, 7 tables, 1 illustration, bibliography, 26 titles. Over 50% of the world’s population has self-perceived sensitive skin. Many of these individuals believe that their skin sensitivity was caused by topical products which caused them to avoid certain skincare products. However, previous research has shown that geographical environments such as weather changes, temperature, pollution, diet, and lifestyle can cause or enhance skin sensitivity. The results from this study failed to confirm the results from earlier studies. Instead, data indicated that geographical environment effects on skin sensitivity were minimal. Moreover, analysis of transepidermal effects on skin sensitivity were minimal. Moreover, analysis of transepidermal water loss for subjects with and without sensitive skin revealed that the skin barrier function for both skin types was not significantly different. Future studies are needed to investigate the sensitivity of the transepidermal water loss for evaluating skin barrier function. In addition, sample size for these studies should be increased to better represent the testing population. Moreover, if the Asian population is used in future clinical research studies, success will be governed by the effectiveness of the educational materials in minimizing the gap between Asian culture and clinical research in this population.Item Safety and Efficacy of Alefacept, Efalizumab, Etanercept, and Infliximab in Treating Moderate to Severe Psoriasis: A Meta-Analysis of Randomized Controlled Trials(2007-05-03) Brimhall, Angela K.; John Licciardone; Roberto Cardarelli; Richard VirgilioBrimhall, Angela K., Master of Science, Clinical Research and Academic Medicine, May 19, 2007, Safety and Efficacy of Alefacept, Efalizumab, Etanercept, and Infliximab in Treating Moderate to Severe Plaque Psoriasis: A Meta-Analysis of Randomized Controlled Trials. Pages=41, Tables=3, Figures=9, Bibliography=61 titles. To evaluate and compare efficacy and safety of biological agents in the treatment of plaque psoriasis, data was identified through four parallel systematic reviews. Randomized, controlled, double-blind, monotherapy trials of alefacept, efalizumab, etanercept and infliximab were selected. Sixteen studies comprising 7,931 patients met inclusion criteria. Efficacy was measured by pooled relative risk (RR) and number needed to treat (NNT) of PASI 75 achievement as compared to placebo. Each biological agent was efficacious (P [less than] .001); however, there was a graded response for achievement of PASI 75. The risk of one or more adverse event was increased in the alefacept, efalizumab, and infliximab groups compared to placebo.